At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed May 6, 2026 at 16:01 ET
Ascendis Pharma reported positive subgroup data from the ApproaCH trial of TransCon CNP (navepegritide) in achondroplasia. Children ≥5 years showed significantly greater annualized growth velocity vs placebo at Week 52 (+1.78 cm/year, p<0.0001) with sustained improvements through Week 104. The drug was already FDA-approved in February 2026; the data strengthens the profile and supports ongoing EU regulatory review.
- Subgroup of children ≥5 years at enrollment: AGV treatment difference +1.78 cm/year vs placebo at Week 52 (p<0.0001)
- Sustained growth improvements observed through Week 104
- Safety profile consistent with overall population; no symptomatic hypotension or bone age acceleration
- TransCon CNP (YUVIWEL) FDA-approved February 2026 for achondroplasia in patients ≥2 years
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access